Keytruda shows nearly 40% CR in high-risk non-muscle invasive bladder cancer unresponsive to standard of care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Merck announced the first presentation of results from an interim analysis of KEYNOTE-057, a phase II trial evaluating Keytruda (pembrolizumab) for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease (Cohort A).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login